4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Sandwich_method_ELISA > 脂肪原/脂联素(人)ELISA试剂盒/AG-45A-0001YTP-KI01/2 x 96孔
商品详细脂肪原/脂联素(人)ELISA试剂盒/AG-45A-0001YTP-KI01/2 x 96孔
脂肪原/脂联素(人)ELISA试剂盒/AG-45A-0001YTP-KI01/2 x 96孔
脂肪原/脂联素(人)ELISA试剂盒/AG-45A-0001YTP-KI01/2 x 96孔
商品编号: AG-45A-0001YTP-KI01
品牌: Adipogen Inc
市场价: ¥15000.00
美元价: 9000.00
产地: 美国(厂家直采)
公司:
产品分类: 夹心法ELISA
公司分类: Sandwich_method_ELISA
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
MoreInformation
ProductDetails
SynonymsACRP30;ADIpoQ;apM1;GBP28;Adipocytecomplementrelatedproteinof30kDa
ProductTypeKit
Properties
ApplicationSetQuantitativeELISA
SpecificityDetectshumanadiponectin.Doesnotcross-reactwithmouseadiponectin,ratadiponectin,humanresistin,humanRELM-βorhumanleptin.
CrossreactivityHuman
Quantity1x96wells
2x96wells(TwinPlex)
Sensitivity100pg/ml
Range0.5to32ng/ml
SampleTypeCellCultureSupernatant
Plasma
Serum
Urine
AssayTypeSandwich
DetectionTypeColorimetric
ShippingandHandling
ShippingBLUEICE
ShortTermStorage+4°C
LongTermStorage+4°C
HandlingAdviceAfterstandardreconstitution,preparealiquotsandstoreat-20°C.
Avoidfreeze/thawcycles.
Plateandreagentsshouldreachroomtemperaturebeforeuse.
Use/StABIlity12monthsafterthedayofmanufacturing.SeeexpirydateonELISAKitbox.
Documents
ManualDownloadPDF
MSDSDownloadPDF
ProductSpecificationSheet
DatasheetDownloadPDF
Adiponectin[ACRP30;AdipoQ]isapromisingbioMarkerofinsulinresistanceandtype2diabetesmellitus(T2DM)butalsoasapotentialtargetformanagementofthemetabolicsyndrome.Itisaveryrobustmarkerthatisnotpronetodegradationoracuteinflammatorychallenges,ispresentinrelativelyhighconcentrationsintheperipheralcirculation,andcanbecollectedbyavarietyofmethods.Thebenefitsofusingadiponectinassaysinclinicalsettingsinclude,(a)predictionofriskofdiabetesandmetabolicstatusand(b)providingatooltomonitormetabolicimprovements.Adiponectinexertsanti-atherogenicandanti-inflammatorypropertiesandmaybeimportantasabiomarkerforobesity-relatedcardiovasculardisease(CVD).NewfindingsshowedurinaryadiponectinexcretionasanindependentnewbiomarkerofmicrovascularandmacrovasculardamageinT2DMandsuggesteditasaverypromisingtoolforearlycardiovasculardiseaseriskassessment.Adiponectinserumlevelwasalsodescribedasagoodbiomarkerofcolorectaladenoma,thisbeingrelatedtothepositivecorrelationbetweenobesityandincreasedriskofcanceratvarioussites(colorectal,breast,prostateandendometrium).
ProductReferences
  1. Plasmaadiponectinlevelsinpostmenopausalwomenwithorwithoutlong-termhormonetherapy:J.Ima;Maturitas54,65(2006)
  2. Associationbetweenhypoadiponectinemiaandcardiovascularriskfactorsinnonobesehealthyadults.J.A.Im,etal.;Metabolism55,1546(2006)
  3. Relationshipofserumadiponectinandresistinlevelswithbreastcancerrisk:J.H.Kang,etal.;J.KoreanMed.Sci.22,117(2007)
  4. ImprovedinsulinsensitivityandadiponectinlevelafterexercisetraininginobeseKoreanyouth:E.S.Kim,etal.;Obesity15,3023(2007)
  5. Associationsofadiponectinwithsexhormone-bindingglobulinlevelsinagingmaleandfemalepopulations:T.Yasui,etal.;Clin.Chim.Acta386,69(2007)
  6. Crosstalkbetweenhigh-molecular-weightadiponectinandT-cadherinduringliverfibrosisdevelopmentinrats:K.Asada,etal.;Intl.J.Mol.Med.20,725(2007)
  7. Retinolbindingprotein4,lowbirthweight-relatedinsulinresistanceandhormonalcontraception:A.Zugaro,etal.;Endocrine32,166(2007)
  8. LeptinisAssociatedwithEndothelialDysfunctioninHealthyObesePremenopausalWomen:K.Kwon,etal.;Kor.Circ.J.37,251(2007)
  9. Correlationbetweenestrogensandserumadipocytokinesinpremenopausalandpostmenopausalwomen:S.C.Hong,etal.;Menopause14,835(2007)
  10. Transgenicmiceexpressingnuclearsterolregulatoryelement-bindingprotein1cinadiposetissueexhibitliverhistologysimilartononalcoholicsteatohepatitis:H.Nakayama,etal.;Metabolism56,470(2007)
  11. Insulin-sensitizingeffectsofexerciseonAdiponectinandRetinolBindingProtein-4concentrationsinyoungandmiddle-agedwomen:S.Lim,etal.;J.Clin.Endocrinol.Metab.93,2263(2008)
  12. RetinolBindingProtein-4elevationisassociatedwithserumTSHlevelindependentlyofobesityinelderlysubjectswithnormalglucosetolerance:S.H.Choi,etal.;J.Clin.Endocrinol.Metab.93,2313(2008)
  13. Fatinliver/musclecorrelatesmorestronglywithinsulinsensitivityinratsthanaBDominalfat:S.Lim,etal.;Obesity17,188(2008)
  14. Obesity-relatedpromotionofaberrantcryptfociinDMH-treatedobesisZuckerratscorrelateswithdyslipidemiaratherthanhyperinsulinemia:T.C.Koch,etal.;Eur.J.Nutr.47,161(2008)
  15. ChangesofSerumAdiponectinLevelsinMurineExperimentalSparganosis:H.J.Yang;Kor.J.Parasitol.46,91(2008)
  16. MasDeficiencyinFVB/Nmiceproducesmarkedchangesinlipidandglycemicmetabolism:S.H.Santos,etal.;Diabetes57,340(2008)
  17. WeightLosswithaLow-Carbohydrate,Mediterranean,orLow-FatDiet:I.Shai,etal.;N.Engl.J.Med.359,229(2008)
  18. Adipose-specificknockoutofraptorresultsinleanmicewithenhancedmitochondrialrespiration:P.Polak,etal.;CellMetab.8,399(2008)
  19. SerumAdipocyteFattyAcid-BindingProteinLevelsAreAssociatedWithNonalcoholicFattyLiverDiseaseinType2DiabeticPatients:J.H.Koh,etal.;Diab.Care32,147(2009)
  20. Elevatedserumg-glutamyltransferaselevelsareindependentlyassociatedwithinsulinresistanceinnon-diabeticsubjects:J.Y.Shin,etal.;DiabetesRes.Clin.Pract.84,152(2009)
  21. TheLou/Crat:Amodelofspontaneousfoodrestrictionassociatedwithimprovedinsulinsensitivityanddecreasedlipidstorageinadiposetissue:C.Veyrat-Durebex,etal.;Am.J.Physiol.Endocrinol.Metab.296,E1120(2009)
  22. MicroRNAExpressioninHumanOmentalandSubcutaneousAdiposeTissue:N.Klöting,etal.;PLoSOne4,e4699(2009)
  23. AdipokinesandSystemicLupusErythematosus:RelationshipwithMetabolicSyndromeandCardiovascularDiseaseRiskFactors:M.Vadacca,etal.;J.Rheumatol.36,295(2009)
  24. Relationshipbetweenserumadipocytokinelevelsandmetabolicsyndromeinmenopausalwomen:H.T.Park,etal.;Gynecol.Endocrinol.25,27(2009)
  25. Circuitresistanceexerciseimprovesglycemiccontrolandadipokinesinfemaleswithtype2diabetesmellitus:S.Kang,etal.;JSSM8,682(2009)
  26. Relationshipbetweengenotypeandserumlevelsofadipokinesandbonemineraldensityintype2diabetesmellituspatients:K.Mirzaei,etal.;Iran.J.Diab.Lip.Dis.8,77(2009)
  27. CombinedImpactofAdiponectinandRetinol-bindingProtein4onMetabolicSyndromeinElderlyPeople:TheKoreanLongitudinalStudyonHealthandAging:S.Lim,etal.;Obesity18,826(2010)
  28. Bodyweightcontrolbyahigh-carbohydrate/low-fatdietslowstheprogressionofdiabetickidneydamageinanobese,hypertensive,type2diabeticratmodel:S.Ohtomo,etal.;J.Obes.2010,136502(2010)
  29. Combinedeffectsofbodymassindexandcardio/respiratoryfitnessonserumvaspinconcentrationsinKoreanyoungmen:J.K.Chou,etal.;Eur.J.Appl.Physiol.108,347(2010)
  30. Adiponectin,ResistinandLeptinResponsetoDietaryInterventioninDiabeticNephropathy:L.Kozlowska,etal.;J.Ren.Nutr.20,255(2010)
  31. PossIBLeinvolvementandthemechanismsofexcesstrans-fattyacidconsumptioninsevereNAFLDinmice:N.Obara,etal.;J.Hepatol.53,326(2010)
  32. Improvedlipidandglucosemetabolismintransgenicratswithincreasedcirculatingangiotensin-(1-7):S.H.Santos,etal.;Arterioscler.Thromb.Vasc.Biol.30,953(2010)
  33. DietarysphingolipidsamelioratedisordersoflipidmetabolisminZuckerfattyrats:K.Yunoki,etal.;J.Agric.FoodChem.58,7030(2010)
  34. Associationofinsulinresistancewithanti-Mullerianhormonelevelsinwomenwithoutpolycysticovarysyndrome(PCOS):H.T.Park,etal.;Clin.Endocrinol.(Oxf)72,26(2010)
  35. Effectsofbodycomposition,leptin,andadiponectinonbonemineraldensityinprepubertalgirls:Y.J.Rhie,etal.;J.KoreanMed.Sci.25,1187(2010)
  36. Adiponectinisproducedbylymphocytesandisanegativeregulatorofgranulopoiesis:L.J.Crawford,etal.;J.Leukoc.Biol.88,807(2010)
  37. Anonthiazolidinedioneperoxisomeproliferator-activatedreceptor/dualagoNISTCG301360alleviatesinsulinresistanceandlipiddysregulationindb/dbmice:H.W.Jeong,etal.;Mol.Pharmacol.78,877(2010)
  38. Adipokinepatterninsubjectswithimpairedfastingglucoseandimpairedglucosetoleranceincomparisontonormalglucosetoleranceanddiabetes:A.Tonjes,etal.;PLoSOne5,e13911(2010)
  39. Bodyweightcontrolbyahigh-carbohydrate/low-fatdietslowstheprogressionofdiabetickidneydamageinanobese,hypertensive,type2diabeticratmodel:S.Ohtomo,etal.;J.Obes.2010,136502(2010)
  40. SerumlevelsofCK18M30andleptinareusefulpredictorsofsteatohepatitisandfibrosisinpaediatricNAFLD:E.Fitzpatrick,etal.;J.Pediatr.Gastroenterol.Nutr.51,500(2010)
  41. Resistin,adiponectinandvisfatin;canadipocytokinespredictgestationaldiabetesmellitusandearlypostpartummetabolicsyndrome?:A.Hossein-nezhad,etal.;Iran.J.Diab.Lip.Dis.9,6(2010)
  42. Combinedeffectsofbodymassindexandcardio/respiratoryfitnessonserumvaspinconcentrationsinKoreanyoungmen:J.K.Cho,etal.;Eur.J.Appl.Physiol.108,347(2010)
  43. Anonthiazolidinedioneperoxisomeproliferator-activatedreceptorα/γdualagonistCG301360alleviatesinsulinresistanceandlipiddysregulationindb/dbmice:H.W.Jeong,etal.;Mol.Pharmacol.78,877(2010)
  44. Organotypiccultureofhumanbonemarrowadiposetissue:K.Uchihashi,etal.;Pathol.Int.60,259(2010)
  45. ADIPOQSNP45associatedwithleanbodymassinphysicallyactivenormalweightadolescentgirls:C.L.Passariello,etal.;Am.J.Hum.Biol.22,813(2010)
  46. Adiponectin,resistinandleptinresponsetodietaryinterventionindiabeticnephropathy:L.Kozłowska,etal.;J.Ren.Nutr.20,255(2010)
  47. Bodyweightcontrolbyahigh-carbohydrate/low-fatdietslowstheprogressionofdiabetickidneydamageinanobese,hypertensive,type2diabeticratmodel:S.Ohtomo,etal.;J.Obes.2010,136502(2010)
  48. Adipocytokinesandbonemineraldensityinadolescentfemaleathletes:R.Gruodyte,etal.;ActaPaediatr.99,1879(2010)
  49. Effectofgreenteaextractonboneturnovermarkersintype2diabeticpatients;Adouble-blind,placebo-controlledclinicaltrialstudy:K.Mirzaei,etal.;DARUJ.Pharm.Sci.17(Suppl1),38(2010)
  50. Phenotypicandgeneticvariationinleptinasdeterminantsofweightregain:G.Erez,etal.;Int.J.Obes.(Lond)35,785(2011)
  51. ApolipoproteinB/A1ratioisassociatedwithfreeandrogenindexandvisceraladiposityandmaybeanindicatorofmetabolicsyndromeinmalechildrenandadolescents:Y.H.Lee,etal.;Clin.Endocrinol.(Oxf)74,579(2011)
  52. CirculatingNamptandRBP4levelsinpatientswithcarotidstenosisundergoingcarotidendarterectomy(CEA):G.Aust,etal.;Clin.Chim.Acta412,1195(2011)
  53. Serumvisfatinisassociatedwithtype2diabetesmellitusindependentofinsulinresistanceandobesity:A.Esteghamati,etal.;DiabetesRes.Clin.Pract.91,154(2011)
  54. RoleofAMP-activatedProteinKinaseandAdiponectinduringDevelopmentofHepaticSteatosisinHigh-fatDiet-inducedObesityinRats:S.K.Ha,etal.;J.Comp.Pathol.145,88(2011)
  55. Adipokines,insulinresistance,metabolicsyndrome,andbreastcancerrecurrence:acohortstudy:S.W.Oh,etal.;BreastCancerRes.13,R34(2011)
  56. Plasmavisfatinandadiponectinconcentrationsinphysicallyactiveadolescentgirls:relationshipswithinsulinsensitivityandbodycompositionvariables:J.Jurimae,etal.;JPEM24,419(2011)
  57. Relationshipbetweeninflammationbiomarkers,antioxidantvitamins,andbonemineraldensityinpatientswithmetabolicsyndrome:Y.Lee,etal.;Nutr.Res.Pract.5,150(2011)
  58. Clinicallysilentadrenaladenomas-theirrelationtothemetabolicsyndromeandtoGNB3C825Tgenepolymorphism:I.Lazurova,etal.;Wien.Klin.Wochenschr.123,618(2011)
  59. Optimalcutpointsofwaistcircumference(WC)andvisceralfatarea(VFA)predictingformetabolicsyndrome(MetS)inelderlypopulationintheKoreanLongitudinalStudyonHealthandAging(KLoSHA):S.Lim,etal.;Arch.Gerontol.Geriatr.54,e29(2012)
  60. EffectsofaerobicexercisetrainingonC1qtumornecrosisfactorα-relatedproteinisoform5(myonectin):associationwithinsulinresistanceandmitochondrialDNAdensityinwomen:S.Lim,etal.;J.Clin.Endocrinol.Metab.97,E88(2012)
  61. GeneticeffectsofadiponectinsinglenucleotidepolymorphismsontheclusteringofmetabolicriskfactorsinyoungKoreanadults:J.Y.Lee,etal.;Eur.J.Appl.Physiol.112,623(2012)
  62. TheeffectsofdetrainingonbloodadipokinesandantioxidantenzymeinKoreanoverweightchildren:J.Woo,etal.;Eur.J.Pediatr.171,235(2012)
  63. Plasmaadiponectinelevationinelderlyindividualswithsubsyndromaldepression:H.G.Jeong,etal.;Psychoneuroendocrinol.37,948(2012)
  64. Leptin,adiponectinandvascularstiffnessparametersinwomenwithsystemiclupuserythematosus:M.Vadacca,etal.;Intern.Emerg.Med.(Epubaheadofprint)(2011)
  65. Changeofcoronaryflowvelocityduringthecoldpressortestisrelatedtoendothelialmarkersinsubjectswithchestpainandanormalcoronaryangiogram:H.J.Hwang,etal.;Clin.Cardiol.35,119(2012)
  66. Efficacyandsafetyofginsam,avinegarextractfromPanaxginseng,intype2diabeticpatients:Resultsofadouble-blind,placebo-controlledstudy:J.W.Yoon,etal.;J.Diabet.Inv.3,309(2011)
  67. Thenormoglycemicfirst-degreerelativesofpatientswithtype2diabetesmellitushavelowcirculatingomentin-1andadiponectinlevels:S.Akbarzadeh,etal.;Cytokine58,295(2012)
  68. High-sensitivityC-reactiveproteinisindependentlyassociatedwitharterialstiffnessinwomenwithmetabolicsyndrome:E.G.Oh,etal.;J.Cardiovasc.Nurs.27,61(2012)
  69. Chitooligosaccharideamelioratesdiet-inducedobesityinmiceandaffectsadiposegeneexpressioninvolvedinAdipogenesisandinflammation:E.H.Choi,etal.;Nutr.Res.32,218(2012)
  70. AMPKactivationwithglabridinamelioratesadiposityandlipiddysregulationinobesity:J.W.Lee,etal.;J.Lipid.Res.53,1277(2012)
  71. Theroleofleptinanditsshort-formreceptorininflammationindb/dbmiceinfusedwithperitonealdialysisfluid:J.C.Leung,etal.;Nephrol.Dial.Transplant.27,3119(2012)
  72. TheValueofVisfatininthePredictionofMetabolicSyndrome:AMulti-FactorialAnalysis:A.Esteghamati,etal.;J.Cardiovasc.Transl.Res.5,541(2012)
  73. Carotidintimamediathickness,brachialflowmediateddilationandprevioushistoryofgestationaldiabetesmellitus:H.Fakhrzadeh,etal.;J.Obstet.Gynaecol.Res.38,1057(2012)
  74. ProgranulinasaPrognosticBiomarkerforBreastCancerRecurrenceinPatientsWhoHadHormoneReceptor-PositiveTumors:ACohortStudy:D.H.Koo,etal.;PLoSOne7,e39880(2012)
  75. MitochondrialDNAcopynumberinperipheralbloodisassociatedwithfemoralneckbonemineraldensityinpostmenopausalwomen:J.H.Kim&D.C.Lee;J.Rheumatol.39,1465(2012)
  76. LowSerumAdiponectinLevelsinKoreanChildrenwithaFamilyHistoryofType2DiabetesMellitus:Y.J.Oh,etal.;Horm.Res.Paediatr.77,382(2012)
  77. ComparisonofregionalbodycompositionanditsrelationwithcardiometabolicriskbetweenBMI-matchedyoungandoldsubjects:Y.Lee,etal.;Atherosclerosis224,258(2012)
  78. Theframinghamriskscore,diet,andinflammatorymarkersinKoreanmenwithmetabolicsyndrome:C.Sohn,etal.;Nutr.Res.Pract.6,246(2012)
  79. Associationbetweenobesityandasthmaintheelderlypopulation:potentialrolesofabdominalsubcutaneousadiposityandsarcopenia:W.J.Song,etal.;Ann.AllergyAsthmaImmunol.109,243(2012)
  80. Omentin-1,visfatinandadiponectinlevelsinrelationtobonemineraldensityinIranianpostmenopausalwomen:M.Tohidi,etal.;Bone51,876(2012)
  81. A12-weekafter-schoolphysicalactivityprogrammeimprovesendothelialcellfunctioninoverweightandobesechildren:arandomisedcontrolledstudy:J.H.Park,etal.;BMCPediatr.12,111(2012)
  82. Adiponectin,leptinandlipidprofilesevaluationinoralcontraceptivepillconsumers:S.Fallah,etal.;Arch.Gynecol.Obstet.285,1747(2012)
  83. Dietaryinterventioninducesflowofchangeswithinbiomarkersoflipids,inflammation,liverenzymes,andglycemiccontrol:R.Golan,etal.;Nutrition28,131(2012)
  84. MetabolicSyndromeisAssociatedwithLowAdiponectinLevelandIncreasedInsulinResistanceinApparentlyHealthyKoreans:K.H.Yoo,etal.;KoreanJ.Obes.21,175(2012)
  85. GastrectomyforEarlyGastricCancerisAssociatedwithDecreasedCardiovascularMortalityinAssociationwithPostsurgicalMetabolicChanges:Y.H.Lee,etal.;Ann.Surg.Oncol.20,1250(2012)
  86. ImplicationofProgranulinandC1q/TNF-RelatedProtein-3(Ctrp3)onInflammationandAtherosclerosisinSubjectswithorwithoutMetabolicSyndrome:H.J.Yoo,etal.;PLOSOne8,e55744(2013)
  87. EffectsofaCombinedAerobicandResistanceExerciseProgramonC1q/TNF-RelatedProtein-3(CTRP-3)andCTRP-5Levels:H.Y.Choi,etal.;DiabetesCare36,3321(2013)
  88. Urinaryadiponectinconcentrationispositivelyassociatedwithmicro-andmacro-vascularcomplications:W.S.Jeon,etal.;Cardiovasc.Diabetol.12,137(2013)
  89. Effectofweightreductionfollowingbariatricsurgeryonserumvisfatinandadiponectinlevelsinmorbidlyobesesubjects:M.J.Hosseinzadeh-Attar,etal.;Obes.Facts6,193(2013)
  90. ImplicationsofC1q/TNF-relatedprotein-3(CTRP-3)andprogranulininpatientswithacutecoronarysyndromeandstableanginapectoris:K.M.Choi,etal.;Cardiovasc.Diabetol.13,14(2014)
  91. Identificationofadipokineclustersrelatedtoparametersoffatmass,insulinsensitivityandinflammation:G.Flehmig,etal.;PLosOne9,e99785(2014)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。